[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-of-alzheimer-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-of-alzheimer-type":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,73,96,119,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100380974","characterizing-variability-in-hearing-aid-outcomes-in-among-older-adults-with-alzheimers-dementia-100380974",false,"NCT04240561","Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia","Inclusion Criteria:\n\n1. Speak English as their primary language\n2. Normal or corrected to normal vision (20\u002F40 binocular vision or unaided using a Snellen chart)\n3. Sensorineural hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 500 and 3000 Hz and a 4 frequency (.5, 1, 2, 3 kHz) pure-tone average of greater than or equal to 30 dB in each ear\n4. Clinical Dementia Rating (CDR) of 0.5 or 1 (indicating slight or mild cognitive impairment in the areas of memory, orientation, judgment\u002Fproblem solving, community affairs, behavior at home\u002Fhobbies, and personal care)\n5. Diagnosis of dementia Alzheimer's type or amnestic mild cognitive impairment (minimum MoCA score of 18).\n6. Living at home\n7. Minimum Grade 10 education\n8. Able to provide own consent as evaluated by the Consent Assessment.\n\nExclusion Criteria:\n\n1. Clinically significant unstable or progressive medical conditions, or conditions which, in the opinion of the investigator(s) places the participant at unacceptable risk if he or she were to participate in the study\n2. History of unresolved communication difficulties following another neurological problem (e.g. stroke or brain tumor), neurodevelopmental disorder (e.g. Down's syndrome), or head\u002Fneck cancer\n3. Positive history of major psychiatric disorder (e.g. schizophrenia, significant untreated depression)\n4. Co-enrolled in other intervention studies targeting hearing, language, or communication strategies\n5. Conductive hearing loss pathology, congenital hearing loss, or fluctuating hearing loss\n6. Current active hearing aid wearer (defined as wearing hearing aid(s) at least 4 hours a day for most days within the past year)","ALL","50 Years","90 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild cognitive impairment. The investigators hypothesize that adults with Alzheimer's dementia represent an extreme case of restricted cognitive ability, such that very low working memory capacity and overall reduced cognitive capacity will limit benefit from advanced signal processing. Thus, the investigators hypothesize that adults with Alzheimer's dementia will receive greater benefit from acoustically simple, high-fidelity hearing aid processing that minimally alters the acoustic signal.",[26,27,28],"Hearing Loss, Sensorineural","Dementia of Alzheimer Type","Amnestic Mild Cognitive Impairment",[30],"mild cognitive impairment","RECRUITING","2026-04-28",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2021-07-01",{"date":39,"type":20},"2027-08-31",{"name":41,"class":42},"Northwestern University","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":15,"minAge":52,"maxAge":17,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100465130","phase-1-assess-fibrin-in-brains-with-adadrd-100465130","NCT05336695","Assess Fibrin in Brains With AD\u002FADRD","Assess the Brain Levels of Fibrin in Alzheimer's Disease and Its Related Dementias Subjects Using 64Cu-FBP8 PET","Inclusion Criteria:\n\n* Age between 55 and 90 years\n* Ability to provide informed consent\n* Specific to healthy volunteers: no history of ADRD\n* Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), MMSE score greater than or equal to 15 and\u002For MOCA greater than or equal to 12\n* Specific to BAnD subjects: referred through the Brain Aging and Dementia (BAnD) research registry\n\nExclusion Criteria:\n\n* MR contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps; ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, ferromagnetic objects such as jewelry or metal clips in clothing\n* Preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest\n* Subjects whose estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin will be excluded from receiving the gadolinium-based contrast agent\n* Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e. 50 millisievert in the prior 12 months)\n* 3\\. In line with published MGH IRB guidelines for pregnancy must be ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. Subjects will not be able to enroll if they are breastfeeding.",true,"55 Years",{"count":54,"type":20},30,[56,57],"PHASE1","PHASE2","The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.",[60,27],"Alzheimer Disease",[60,62],"Dementia","2025-10-28",{"date":65,"type":35},"2025-10-30",{"date":67,"type":35},"2022-03-29",{"date":69,"type":20},"2026-09-28",{"name":71,"class":42},"Massachusetts General Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":72},"100538584","autonomic-involvement-in-patient-with-cognitive-decline-100538584","NCT06292741","Autonomic Involvement in Patient With Cognitive Decline","Evaluation of the Prevalence of Autonomic Nervous System Involvement in Patients With Cognitive Impairment by a Non-invasive Combined Study of Dysautonomia","Inclusion Criteria:\n\n* male and females between 50 and 85 years\n* cognitive decline (dementia, lewy's body dementia, Parkinson dementia, Alzheimer dementia)\n* mild cognitive decline ( lewy's body MCI, Parkinson MCI and Alzheimer MCI)\n* Ability to assume the upright position\n\nExclusion Criteria:\n\n* diabetes mellitus\n* eye problems\n* severe cognitive decline\n* heart disease\n* peripheral neuropathy\n* language barrier\n* oncological disease\n* medical pathologies associated with cognitive deficits","85 Years",{"count":82,"type":20},120,[23],"Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline",[86,27],"Dementia, Mild","2025-08-25",{"date":89,"type":35},"2025-08-26",{"date":91,"type":35},"2023-01-11",{"date":93,"type":20},"2026-01",{"name":95,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":15,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":72},"100435924","reducing-african-americans-alzheimers-risk-through-exercise-mild-cognitive-impairment-raate-mci-100435924","NCT04956549","Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)","Reducing African Americans' Alzheimer's Disease Risk Through Exercise-Mild Cognitive Impairment Cohort","RAATE-MCI","Inclusion Criteria:\n\n1. are African American (self-identify)\n2. are 60 and older\n3. are physically capable of exercise\n4. are willing to accept randomization\n5. are willing to attend group sessions\n6. plan to live in the study area over the next 13 months and capable of traveling to designated study facility for clinic visits and intervention sessions for the next year\n7. are free of conditions (e.g. uncontrolled asthma, severe sickle cell disease, etc.) that would make regular exercise unsafe as deemed by the medical investigator\n8. have not engaged in regular physical activity\n9. have a Short Physical Performance Battery ≥4\n10. physically capable of exercise\n11. are unable to utilize devices and\u002For applications as required for study participation\n12. willing to attend group sessions\n13. willing to allow researchers to use data for research purposes after study participation is completed\n14. meet criteria for MCI as defined by the NIA-AA research framework a. cognitive performance below normal range (score \\\u003C 1.5 SDs below the mean on NIH Toolbox scores for their age and sex on at least one of the subtests)\n\nExclusion Criteria:\n\n1. have cognitive impairment that would interfere with participating in a group discussion\n\n   a. cognitive performance in the demented range (score \\\u003C 3 SDs below the mean on NIH Toolbox scores for their age and sex on at least one of the subtests)\n2. meet criteria for dementia\n3. are unwilling to give written informed consent or accept randomization in either study group\n4. are too active (as defined by ≥10 min bouts of MVPA as measured by Actigraph) if:\n\n   1. Sum of MVPA bouts for the 7 day wear period ≥40 mins\n   2. Or ≤40 mins of MVPA 10min bouts AND ≥3 days of bouts\n5. have uncontrolled hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 90 mmHg).\n6. have had a myocardial infarction, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis, pulmonary embolus, hip fracture, hip or knee replacement, or spinal surgery in the past 6 months\n7. are undergoing cardiopulmonary rehabilitation\n8. have uncontrolled diabetes that in the judgment of the MI may interfere with study participation\n9. have clinically diagnosed osteoporosis that in the judgment of the MI may interfere with study participation\n10. are currently enrolled in another randomized trial involving lifestyle or pharmaceutical interventions\n11. have another member of the household that is a participant in RAATE or RAATE MCI\n12. refuse to participate in the study without disclosure of their amyloid PET scan results\n13. refuse to allow anonymized versions of their study data for research after this study is completed.\n14. have other medical, psychiatric, or behavioral factors that in the judgment of the Principal or Medical Investigator may interfere with study participation or the ability to follow the intervention protocol","60 Years",{"count":106,"type":20},144,[23],"The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and older will be recruited.",[27],"2025-03-12",{"date":112,"type":35},"2025-03-17",{"date":114,"type":35},"2021-06-01",{"date":116,"type":20},"2027-03-31",{"name":118,"class":42},"Pennington Biomedical Research Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":51,"sex":15,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":43},"100507909","uppsala-dalarna-dementia-and-gait-project-100507909","NCT05893524","Uppsala-Dalarna Dementia and Gait Project","UDDGait™","Inclusion Criteria:\n\n* Patients undergoing memory assessment at at Uppsala University Hospital, Sweden\n* Patients undergoing memory assessment at at Falu Hospital, Sweden\n* Cognitively unimpaired individuals with a Mini Mental State Examination (MMSE) score of \\> 26\n\nExclusion Criteria:\n\n* Inability to walk three meters back and forth\n* Inability to rise from a sitting position\n* Indoor use of a walking aid\n* Current or recent hospitalization (within the last 2 weeks)\n* Need of an interpreter to communicate in Swedish","37 Years","94 Years",{"count":129,"type":20},550,"OBSERVATIONAL","UDDGait™ is a multidisciplinary research project with the overreaching goal of providing an aid for early identification of cognitive impairment and risk of dementia development, thereby providing a basis for adequate symptom relieving and health promoting interventions.\n\nA new concept is investigated for this purpose: a \"dual-task-test\", which implies the combination of a well-established mobility test (Timed Up-and-Go, TUG) with a simultaneous verbal task (i.e. TUG dual-task, TUGdt). This type of test has been judged as a potential aid for early identification of dementia disease. More research is needed to further examine the test's validity, reliability and predictive capacity.\n\nThe overall aim is to investigate if TUGdt is useful as an aid for prediction of dementia disease. To ensure the results, the aim is also to evaluate the test's measurement properties and to generate normative reference values of healthy control persons.",[62,133,134,27,135,136],"Dementia, Mixed","Dementia Senile","Mild Cognitive Impairment","Subjective Cognitive Impairment",[138,139,140,62,135,136,141,142,143],"Timed Up-and-Go, TUG","TUG dual-task","Cognitive tests","Alzheimer's disease","Step parameters","Video recorded tests","2025-02-11",{"date":146,"type":35},"2025-02-12",{"date":148,"type":35},"2015-04-09",{"date":150,"type":20},"2026-12-24",{"name":152,"class":42},"Dalarna University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100500421","an-observational-study-of-patients-living-with-chronic-neurological-diseases-100500421","NCT05796037","An Observational Study of Patients Living With Chronic Neurological Diseases","Disease Cohort\n\nInclusion Criteria:\n\n•Adult patients at the time of enrollment with a diagnosis of ADRD, MCI, PD, or MS by select ICD-10 codes in the EHR interface\n\nExclusion Criteria:\n\n* Death\n* Manual removal (sponsor or site request)\n* No EHR interface encounter \\> 3 years\n\nEngaged Cohort\n\nInclusion Criteria:\n\n* Adult patients diagnosed and managed for these conditions invited to participate\n* Ability to provide written informed consent (or have a legally authorized representative to provide informed consent)\n* Care partners may be invited to participate in surveys and will provide informed consent.\n\nExclusion Criteria:\n\n* Patient expressed desire to withdraw consent to complete PROs\n* Care partner expressed desire to withdraw consent to complete PROs\n* Failure to complete PROs within 24 weeks of initial invitation\n* Greater than 24 months lapse of survey completion after baseline surveys completed\n* Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort\n\nAge Cohort\n\nInclusion Criteria:\n\n•Adult patients aged 60 and older at time of enrollment\n\nExclusion Criteria:\n\n* Death\n* Manual removal (sponsor or site request)\n* No EHR interface encounter \\> 3 years","18 Years",{"count":161,"type":20},1500000,"TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment (MCI), Parkinson's disease (PD), and multiple sclerosis (MS).",[164,27,60,135,165,166],"Neurological Diseases or Conditions","Parkinson Disease","Multiple Sclerosis","NOT_YET_RECRUITING","2024-11-18",{"date":170,"type":35},"2024-11-20",{"date":172,"type":20},"2025-03-31",{"date":174,"type":20},"2038-12-31",{"name":176,"class":177},"Target PharmaSolutions, Inc.","INDUSTRY"]